Zentiva €4.1B Sale Marks Europe’s Largest Private Equity Healthcare Exit of 2025
Advent International has agreed to sell Prague-based generic pharmaceutical company Zentiva to U.S. private equity firm GTCR for €4.1 billion ($4.8 billion), making it the largest private equity healthcare exit in Europe this year. The transaction follows a competitive bidding process and significantly boosts the region’s healthcare exit value for 2025 to €23.7 billion—already exceeding […]
Continue Reading